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Abstract 
Twenty one years after the Oviedo Convention, which highlighted the need for coordination 
and cooperation between countries “so that humanity can benefit from technological 
advancements in the field of Biology and Medicine” and having already experienced the 
consequences of the lack of a common European legislation regarding the application of the 
assisted reproduction methods, the rapid scientific and technological progress in the field of 
assisted reproduction, the “new genomic technologies” -as they are widely known- poses a 
number of crucial questions of medical, ethical and legal prospect. One cannot but wonder 
whether the novel assisted reproduction methods constitute a new challenge for the Article 3 
of the Oviedo Convention that safeguards the equal access to health care.  
The discrimination among European citizens in accessing the technological achievements in 
the field of assisted reproduction because of the different types of legislation adopted in each 
country, the growth of the so called “reproductive tourism” and -at the same time- the 
evolution of even more extensive methods, that are now accessible at a really low cost, make 
more clear the need for the legal framework of the Oviedo Convention to be transformed in a 
common European Regulation that abides by Article 3 of the Oviedo Convention defending 
equality of access to health care. 
 
I. Introduction 
Twenty one years after the Oviedo Convention, which highlighted the need for coordination 
and cooperation between countries “so that humanity can benefit from technological 
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advancements in the field of Biology and Medicine”1 and though significant steps have been 
made, there still remain major differences between the various national legal frameworks 
regarding the applications of biotechnology and especially regarding the application of assisted 
reproduction methods.  
The Convention of Oviedo, being a framework, deals with a vast number of issues, 
associated with the application of Biotechnology on human beings. The limited reference to the 
methods of assisted reproduction in the Oviedo Convention should be associated with the fact 
that differences in the national and cultural heritage did not allow to reach a consensus on a 
number of issues, such as the determination of the specific time-point at which life begins, the 
nature of the genetic material, the fertilized egg and embryo, the freedom to research e.tc. One 
should always bear in mind that many of the member-states of the European Council did not 
sign the treaty. 
However, the European countries, realizing that a lot of issues arise concerning the risks 
associated with the application of the methods of assisted reproduction and the extent of the 
application, they have instituted laws governing this application at a national level. The thing is 
that these laws were brought into power at different time points across the various countries, 
depending on the progress in each country and the strictness or leniency of these laws reflect 
each country’s position on the above mentioned crucial issues2. 
This means that, although the Oviedo Convention leads the way, the mosaic of national 
legislations concerning the application of reproductive technology causes major problems forty 
one years after the birth of the first child by artificial insemination, Louise Brown. The chances 
are that the advancements being made in this field, such as the novel assisted reproduction 
methods, are going to worsen the situation and the lack of a common European regulation is 
                                                          
1
 Oviedo Convention Preamble. 
2
 Further information concerning the national legislation on assisted reproduction of seven European Countries, 
(France, Germany, Greece, Ireland, Italy, Sweden, United Kingdom) can be found in 
http://repro.law.auth.gr/en/research_content. See also, Assisted Reproduction in Europe: social, ethical and legal 
issues, Publications of Medical Law and Bioethics, vol. 20 II, Sakkoulas Publications, Athens-Thessaloniki, 2015 and 
Medically Assisted Reproduction: Towards a common European legislation?, Publications of Medical Law and 
Bioethics, vol. 21 II, Sakkoulas Publications, Athens-Thessaloniki, 2015. 
 Βιο-Νομικά – Bio-Juria 
Τομ. 1, τεύχ. 1 (2019) – Vol. 1, iss. 1 (2019) 
E-ISSN: 2654-119X 





more obvious than ever, nowadays that the new genomic technologies, as a part of assisted 
reproduction technology, allow affordable gamete donor testing at a large scale.  
The “genetic screening of the donors” -as it is widely known- poses a number of crucial 
questions of medical, ethical and legal prospect and one can only wonder whether the novel 
assisted reproduction methods, such as genetic screening, constitute a new challenge for the 
Article 3 of the Oviedo Convention that safeguards the equal access to health care.  
II. Health and Equitable access to health care 
To answer to this question one should bear in mind two basic definitions: 1st the 
definition of “health” given in the preamble of the Constitution of the World Health 
Organization in 1946 and 2nd the provisions of the Oviedo Convention regarding the “equitable 
access to health care”.  
a. According to the Preamble to the Constitution of the World Health Organization, 1946 
“Healthis a state of complete physical, mental, and social well-being and not merely the absence 
of disease or infirmity”. 
As stated by the World Health Organization, health describes more than the mere 
integrity of the physical body. It depicts the wholesomeness of a human being understood as a 
composition of bodily, emotional, intellectual and social as well as material parts, in which the 
conditionality of the individual aspects to one another is acknowledged and respected3.  
b. Article 3 of the «European Convention for the Protection of Human Rights and Dignity 
of the Human Being with regard to the Application of Biology and Medicine: Convention on 
Human Rights and Biomedicine», or- in other words -the «Oviedo Convention» states that: 
“Parties, taking into account health needs and available resources, shall take appropriate 
measures with a view to providing, within their jurisdiction, equitable access to health care of 
appropriate quality”.  
                                                          
3
S.Kühn/U.-M. Rieger, “Health is a state of complete physical, mental and social well-being and not merely the 
absence of disease or infirmity”, Surgery for Obesity and Related Diseases 2017 May;13(5):887. 
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Article 3 is one of the general norms of the Convention that are contained in Chapter I 
(Articles 1-4) and, directly inspired on the idea of human dignity, indicates that the States 
should take adequate measures in order to provide equitable access to health care of 
appropriate quality. 
According to that provision States must not only eliminate unjustified discrimination in 
the access to health care system, but also actively ensure a minimum of medical care for their 
citizens4. However, given the fact that the resources regarding the health care always have and 
always will be scarce or limited, the Article 3 of the Convention clarifies that these measures 
needed are to be adopted taken into account the available resource of each State. In other 
words, Article 3 of the Convention functions just as an urge to the States to make all possible 
efforts demanded to ensure equitable access to health care5. 
III. Health Care Right and Assisted Reproduction  
Taking into account the two above mentioned provisions one could easily wonder 
whether assistance to reproduction in general and more specifically access to the new assisted 
reproduction technologies, such as extended genetic screening, should be included in what is 
called “basic health care” for which all citizens are supposed to be entitled and if so whether 
reimbursement is in order6.  
a. As one could easily understand, determining what constitutes “basic health care” is 
very difficult and all in all depends on economics, that is on how much a particular nation can 
afford to spend to health care given other needs and investments. After all, that is what the 
Oviedo Convention states, as well (“…taking into account health needs and available resources 
…”). But, at the same time it is also in part a matter of medicine: what treatments are the most 
                                                          
4
R. Andorno, “The Oviedo Convention: A European Legal Framework at the Intersection of Human Rights and 
Health Law”, Journal of International Biotechnology Law 2(4):133-143, January 2005, p. 138. 
5
 Explanatory Report to the Convention on Human Rights and Biomedicine, Paragraph 26. 
6
 ESHRE, Task Force on Ethics and Law 14: Equity of access to assisted reproductive technology, Human 
Reproduction Vol.23, No.4 pp. 772–774, 2008. 
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effective in a given set of circumstances or what treatment should be considered the standard 
of care?7 
The right to health care is usually interpreted as a right to a “descent minimum”. For 
most people this means something like access to primary and preventive care, prenatal and 
well baby-care, necessary hospitalization, mental health and substance abuse services, specialty 
care when called for and perhaps prescription of drugs.  
b. It has always been a matter of appreciation and controversy whether assistance to 
reproduction could be considered as a part of the so called basic (descent) health care. Not all 
European Countries include infertility treatment in the basic health care budget and the answer 
depends on the general level of welfare of society. Partial or whole public funding depends on 
economic affluence, but should also be related to medical effectiveness of the application, the 
number of treatments and the possibility of secondary infertility, as well as the number of other 
children, according to the European Society of Human Reproduction (ESHRE)8.  
When it comes to reproductive health and assisted reproduction what is generally being 
accepted is that people should be able to have a satisfying and safe sex life and that they should 
also enjoy having the capability to reproduce and the freedom to decide if, when and how often 
to do so. That’s why people perceive suffering from infertility as very real and as compromising 
their health9. In other words, infertility is a health condition and should be confronted as such. 
But, the wish to reproduce is of great significance not only to people suffering from 
infertility. There are also people who need to have access to assisted reproduction techniques 
in order to prevent the birth of a child with a specific genetic disorder. As in In Vitro Fertilization 
combined with Preimplantation Genetic Diagnosis may be the only therapeutic option 
                                                          
7
M.-A. Ryan, Ethics and Economics of Assisted Reproduction: The Cost of Longing, Georgetown University Press, 
2001, p.122 et seq. 
8
 ESHRE Task Force on Ethics and Law 14: Equity of access to assisted reproductive technology, Human 
Reproduction Vol.23, No.4 pp. 772–774, 2008. 
9
J. Schenker, Ethical Dilemmas in Assisted Reproductive Technologies, De Gruyeter, 2011, p. 43. 
 Βιο-Νομικά – Bio-Juria 
Τομ. 1, τεύχ. 1 (2019) – Vol. 1, iss. 1 (2019) 
E-ISSN: 2654-119X 





available, funding is also appropriate, as the European Society of Human Reproduction (ESHRE) 
states10. 
However, the situation is not that clear when it comes to the huge conversation of 
whether assisted reproduction should remain “open” to everybody for whatever reason. 
Homosexual men or women, people in prison, models, actresses, career women without facing 
any medical need should they have access to assisted reproduction? Is a very ample perception 
of the term “medical necessity”11 in order? And if so, should these treatments be funded by the 
State or are we talking about out-of-pocket money? Usually the segmentation being made is 
between those who believe that infertility is a disease and that’s why access to assisted 
reproduction methods should only be allowed due to medical reasons (e.g. blocked Fallopian 
tubes, prevention of birth of a child with genetic disorder) and those who regard the access to 
assisted reproduction methods as an expression of personal autonomy and as a fulfillment of 
one’s reproductive choices no matter the reason of “infertility”. The whole, partial or no state 
funding of the procedure differs largely from one country to another creating a series of 
problems especially nowadays that intraborder transportation is very easy and the Internet 
market very tempting. 
IV. Equitable access to health care and Novel Assisted Reproduction Methods in view of 
Article 3 of the Oviedo Convention 
Coming to the Νovel Assisted Reproductive Methods the situation is now somehow 
more complicated for the new genomic technologies, that now allow affordable gamete donor 
testing at a large scale and at a low cost, are only expected to point out the lack of common 
rules and the inequality of access among European citizens. We have already experienced the 
discrimination among European citizens in accessing the technological achievements in the field 
                                                          
10
 ESHRE, Task Force on Ethics and Law 14: Equity of access to assisted reproductive technology, Human 
Reproduction Vol.23, No.4 pp. 772–774, 2008. 
11
M. Milapidou, “Medical Inability as a prerequisite for access to Medically Assisted Reproduction”, Publications of 
Medical Law and Bioethics, vol. 21 II, Medically Assisted Reproduction: Towards a common European legislation?, 
Sakkoulas Publications, Athens-Thessaloniki, 2015, p.55 et seq. 
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of reproduction because of the different types of legislation adopted in each country12. At the 
same time it is estimated that in Europe 10.000 – 15.000 patients cross the borders of their 
countries every year in order to bypass prohibiting or strict legislative frameworks in assisted 
reproduction13 without having any guarantee that this choice will be carefree14.The lack of a 
European common ground regarding the rules regulating these applications has already lead 
and will continue leading to more and more crucial problems, especially now that even more 
extensive methods are accessible and that’s why a new regulation is in order. 
But what are the main issues deriving from the application of new genomic technologies 
and in what way do they collide with the right to equal access to health? 
a. First of all controversy exists among professional guidelines with regards to what 
exactly genetic screening should include. Nowadays, the rapid progress of medical science 
allows the extensive genetic screening of donors for a variety of diseases that may be 
transmitted to the child at a low actual cost. Should these methods be applied at a large scale in 
view of what Oviedo Convention calls “equitable access to health care of appropriate quality 
according to health needs and available resources”? 
The proponents of this practice support the full use of technology in order to minimize 
the chances of a disease transmission to the offspring. The opponents claim that the attempt to 
eliminate genetically transmitted diseases is an utopic project, which can be derailed towards 
eugenics and at the same time reduce the number of the possible donors. The question that 
                                                          
12
 There is a clear distinction between strict (e.g. Germany, Italy) and more lenient (e.g. United Kingdom, Greece) 
legislations. 
13
F. Shenfield, “Crossing Borders for gametes donation and surrogacy: a legal puzzle?”, Publications of Medical Law 
and Bioethics, vol. 20 II, Assisted Reproduction in Europe: social, ethical and legal issues, Sakkoulas Publications, 
Athens-Thessaloniki, 2015, p.375 et seq. 
14
 Decisions Mennesson and Labassee vs France of the European Court of Human Rights are a crystal clear example 
of the situation that has been created - T. Trokanas, “Recent jurisprudential developments on the subject of 
surrogate motherhood: the cases Mennesson and Labassee versus France before the European Court of Human 
Rights”, Publications of Medical Law and Bioethics, vol. 20 II, Assisted Reproduction in Europe: social, ethical and 
legal issues, Sakkoulas Publications, Athens-Thessaloniki, 2015, p.175 et seq. 
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arises is therefore to what extent15 the donor can be tested and it should be answered at a 
European level. 
According to present recommendations provided for evaluation of gamete donors, 
genetic screening mainly consists of a medical evaluation, an extensive family history of the 
donor taken by a genetics’ professional as well as additional tests performed for specific serious 
genetic disorders16. The donor should not have any significant hereditable condition, including 
major Mendelian disorders, major malformations, important familial disorders with a major 
genetic component or a chromosomal rearrangement that may not result in healthy gametes. 
Professional guidelines of different EU countries have recommended that donors should 
undergo general population tests and should additionally have ethnicity-based testing for 
further autosomal recessive disorders with a higher frequency in the relevant population. 
Predictably, such cases might lead to societal and ethical concerns about whether the present 
guidelines for genetic testing of donors are adequate.Some common bases have already been 
set by the Articles 3 and 4 of Annex III of the Directive 2006/17/EC of February 8, 2006, as 
amended by the Directive 2012/39/EU of 26 November 2012. The Directive 2006 / 17 / EU 
details the minimum of checks to be carried out on donors of reproductive cells. 
The major issue, however that derives from the extended donors’ screening is the 
possibility of donors’ elimination because of the extended screening. 
b. Moreover, the issue of the control and the security of the whole process- as part of 
access to health care- is being questioned by intraborder In Vitro Feritlization, the so called 
“reproductive tourism”, a fast-growing practice. That mobility raises serious legal questions 
regarding the responsibility of the treating physician, the cryopreservation bank and the 
Assisted Reproduction TechnologyUnit in cases of: i) using genetic material of questionable 
quality, ii) non-compliance with safety rules and standards, iii) lack of genetic counseling, iv) 
purchase of genetic material via the Internet, v) lack of informed consent. It is more than 
                                                          
15
J. Kaye et al., Ethical implications of the use of whole genome methods in medical research, European Journal of 
Human Genetics (2010) 18, p.398–403. 
16
W. Dondorp et al., ESHRE Task Force on Ethics and Law 21: genetic screening of gamete donors: ethical issues, 
Human Reproduction, Vol.0, No.0 pp. 1 –7, 2014, P. Eydoux et al, “How can the genetic risks of embryo donation 
be minimized?”, Human Reproduction Vol.19, No.8 pp. 1685–1688, 2004. 
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obvious that the new genomic technologies will only point out in a more strong way the related 
dangers. 
c. Another important point to consider is whether the State should cover, through the 
national health system, the cost of all the tests which are medically possible, in order to ensure 
the birth of a healthy child, thus increasing exorbitantly the budget of the national health 
system. The in-depth analysis of this issue raises legal and ethical issues that should be 
investigated based on the rules of the economic analysis of law. 
V. Epilogue 
These issues arising due to constant biotechnological evolution in the area of Assisted 
Reproduction Technology and genetic research cannot obviously be eliminated. However, a 
common ground among different national European laws could and should be found, so that 
the aforementioned issues are tangled in a way that guarantees the equal and safe access to 
assisted reproduction methods for the people interested, in a way that complies with Article 3 
of the Oviedo Convention. 
Such a common regulation should be based on a multidimensional approach in order to 
cover the multiple medical, ethical and legal issues deriving from the application of assisted 
reproduction methods. Taking into consideration Article 3 of Oviedo Convention regarding the 
equal access to health care and bearing in mind the rapid progress of this scientific field it is of 
paramount significance to regularizein a common way the processes and safeguard the rights of 
the individuals involved. One can easily understand that a specific and common European 
regulation will be in favor of both those undergoing assisted reproduction technology methods 
and the specialists applying these methods and may be held responsible. 
This approach will ensure that the proposed legislation is realistic and can be applied 
immediately. As such and successfully addressing the inherent problems and shortcomings in 
the legislation, is expected to lead to a sharp decline in the number of infarctions associated 
with application of ART. That would also lead to reduction of the load on the judiciary, with 
obvious benefits to economy and society. Likewise, streamlining issues associated with 
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reproductive tourism will not only be beneficial to individuals and societies, but could also 
boost local economies. 
 
 
